Aspirin does help prevent blood clots, but through a specific and somewhat narrow mechanism: it blocks platelets from sticking together, which makes it effective against the kind of clots that form in arteries and far less reliable against clots that develop in veins. That distinction matters enormously for who should take it and why. The story of aspirin as a clot-preventing drug is also a story about trade-offs, because the same property that keeps dangerous clots from forming also makes bleeding easier, and the balance between those two effects shifts depending on your health history, your age, and what other medications you take.
How Aspirin Stops Clots From Forming
Aspirin’s clot-preventing ability traces back to a single chemical trick. It permanently disables an enzyme in platelets called cyclooxygenase-1, which platelets need to produce thromboxane A2, a molecule that tells other platelets to activate and clump together. Because platelets have no nucleus and cannot make new proteins, once aspirin knocks out their cyclooxygenase, they stay knocked out for their entire lifespan of about seven to ten days. That is why even a small daily dose can keep platelet clumping suppressed around the clock. A Bayer chemist first synthesized aspirin in 1897, though it took another seventy years before researchers worked out how it interfered with prostaglandin production, the pathway that explained both its anti-inflammatory and antiplatelet effects.1PubMed. The first 3500 years of aspirin history from its roots – A concise summary
Where the Evidence Is Strongest
If you have already had a heart attack, a stroke, or another cardiovascular event, aspirin is one of the most studied and well-supported treatments for preventing another one. It was established more than a quarter century ago as a standard therapy to reduce recurrent cardiovascular events in people with coronary artery disease.2PubMed. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease In this context, the benefit is relatively clear-cut: the risk of another clot-driven event is high enough that the reduction in clotting outweighs the added bleeding risk for most people. Cardiologists refer to this use as “secondary prevention” because you are preventing a second event, not a first.
The picture gets much murkier when the question is whether healthy people without a history of cardiovascular disease should take daily aspirin to prevent a first event. This is “primary prevention,” and the guidelines have shifted dramatically in recent years. For decades, doctors prescribed low-dose aspirin to broad swaths of middle-aged adults considered at moderate cardiovascular risk. More recent large trials, particularly in older adults, showed the bleeding risks are harder to justify when the baseline chance of a heart attack or stroke is lower. A study examining guideline concordance found that roughly half of adults using aspirin for primary prevention were doing so in ways potentially inconsistent with current recommendations, with common reasons for mismatch including advanced age, conditions that increase bleeding risk, or simultaneous use of other drugs that compound that risk.3Blood Advances. Guideline concordance of aspirin use for primary prevention in adult outpatients
Arterial Clots Versus Venous Clots
One of the most common misunderstandings about aspirin is assuming it works equally well against all types of blood clots. It does not. Arterial clots, the kind that trigger heart attacks and most strokes, form when platelets pile onto a ruptured plaque inside an artery. Because aspirin targets platelet activation, it is well suited to this type of clot. Venous clots, like deep vein thrombosis (DVT) or pulmonary embolism, form through a different process that depends more on slow blood flow and the coagulation cascade, the chain reaction of clotting proteins in the blood. Aspirin has only a modest and often statistically uncertain effect on venous clots.
A meta-analysis of aspirin use in patients with antiphospholipid antibodies, a group prone to clotting, illustrated this divide: aspirin cut the risk of arterial clots by about half but showed no statistically significant reduction in venous clots.4PubMed. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis This is why doctors prescribe anticoagulants rather than aspirin when the primary concern is a venous clot. The two drug classes work on different parts of the clotting system and are not interchangeable.
The Bleeding Tradeoff
Every conversation about aspirin’s clot-preventing benefits has to grapple with its main downside: bleeding. The same mechanism that prevents harmful clots also makes it harder for the body to stop bleeding once it starts. This shows up in two places that matter clinically: the gut and the brain.
In the gut, aspirin damages the stomach lining directly while also impairing the platelets that would normally help seal small erosions. Chronic use is associated with gastric ulcers and with bleeding episodes like vomiting blood or dark tarry stools. Research indicates that both an ulcer-causing effect and an anti-clotting effect contribute to these presentations, meaning aspirin attacks the problem from two directions at once.5Alimentary Pharmacology & Therapeutics. Review article: aspirin and gastrointestinal bleeding
In the brain, the concern is intracranial bleeding, a rare but potentially devastating event. A systematic review pooling eight trials of low-dose aspirin in people without symptomatic cardiovascular disease found that aspirin raised the risk of any intracranial hemorrhage by about 37 percent compared with a placebo. In absolute terms, that translated to roughly two additional intracranial bleeds per thousand people treated.6JAMA Neurology. Frequency of Intracranial Hemorrhage With Low-Dose Aspirin in Individuals Without Symptomatic Cardiovascular Disease: A Systematic Review and Meta-analysis The ASPREE trial, which focused specifically on healthy adults over 70, confirmed a significantly higher rate of intracranial bleeding in the aspirin group compared with placebo.7PubMed Central. Low-Dose Aspirin and the Risk of Stroke and Intracerebral Bleeding in Healthy Older People Those absolute numbers are small, but for someone whose baseline risk of a clot-driven event is also small, the math can tip against aspirin.
Finding the Right Dose
Aspirin doses for pain relief, typically 500 to 1,000 milligrams, are far higher than what is used for clot prevention. The antiplatelet effect can be achieved with much less. A review of the evidence concluded that daily doses of 75 to 81 milligrams appear to optimize the balance between preventing clots and minimizing bleeding, especially for long-term use.8PubMed. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding In the United States, the standard “baby aspirin” or “low-dose aspirin” tablet is 81 milligrams, which falls right in that range. Higher doses do not appear to provide additional clot protection but do increase the risk of stomach bleeding and other complications.
There is some nuance around whether enteric-coated tablets, which dissolve in the intestine rather than the stomach, reduce gut damage. The coating delays absorption, and some researchers have questioned whether that delay affects how reliably platelets are inhibited, but enteric-coated formulations remain widely used and generally accepted for chronic prevention.
When Aspirin Does Not Work as Expected
Not everyone who takes aspirin gets the same antiplatelet effect. Researchers use the term “aspirin resistance” to describe situations where the expected suppression of platelet activity either does not happen or is weaker than predicted. The accumulating evidence suggests that people with high residual platelet reactivity while on aspirin face a greater risk of major cardiovascular events, including heart attacks and strokes.9PubMed. A contemporary viewpoint on ‘aspirin resistance’
The reasons for this variability are not fully pinned down. Poor absorption, interactions with other anti-inflammatory drugs like ibuprofen (which can compete for the same enzyme binding site), genetic differences in platelet biology, and even the timing of the dose can all play a role. The term “resistance” has been applied both to measurable laboratory findings and to clinical events where a patient has a clot despite taking aspirin as prescribed.10PubMed. High platelet reactivity and antiplatelet therapy resistance Whether routine testing for aspirin resistance should guide treatment decisions remains an open question. Most guidelines do not currently recommend it, partly because it is unclear what to do differently when resistance is detected.
Why Stopping Suddenly Is Risky
If you have been on daily aspirin for cardiovascular protection, stopping abruptly is one of the worst things you can do. A large Swedish population-based study found that patients who discontinued aspirin had a 37 percent higher rate of cardiovascular events than those who continued, which worked out to one additional event per year for every 74 people who stopped. The risk rose shortly after discontinuation and did not appear to fade over time.11PubMed. Low-Dose Aspirin Discontinuation and Risk of Cardiovascular Events: A Swedish Nationwide, Population-Based Cohort Study
The explanation involves a rebound phenomenon. When aspirin is withdrawn, the body begins producing new platelets that are no longer inhibited, and there is evidence that these fresh platelets may actually be more reactive than normal for a period. Animal studies have shown that while an antithrombotic effect persists for a few days after a single aspirin dose, a prothrombotic swing appears roughly a week to ten days later. In humans, researchers have found elevated platelet activity weeks after stopping aspirin, and one study reported a more than threefold increase in the odds of ischemic stroke in the four weeks after discontinuation.12JAMA Neurology. Effect of Discontinuing Aspirin Therapy on the Risk of Brain Ischemic Stroke The clinical takeaway is straightforward: aspirin withdrawal has been associated with an increased risk of thrombotic events in both clinical and basic research.13PubMed. Aspirin discontinuation syndromes: clinical implications of basic research studies If there is a medical reason to stop, a doctor should supervise the process rather than the patient simply running out of pills and not refilling.
Protecting the Stomach
For people who need long-term aspirin but are at higher risk of gastrointestinal problems, acid-suppressing medications called proton pump inhibitors (PPIs) can significantly reduce the damage. A meta-analysis of ten randomized controlled trials found that PPIs decreased the risk of upper gastrointestinal ulcers associated with low-dose aspirin by about 84 percent and reduced bleeding by about 73 percent.14PubMed Central. Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view This co-prescribing is already standard practice for patients on dual antiplatelet therapy or those with a history of stomach ulcers, but it is sometimes overlooked in lower-risk patients who still develop symptoms over time.
Aspirin in Pregnancy
One of aspirin’s more specialized roles is in preventing pre-eclampsia, a dangerous pregnancy complication marked by high blood pressure and organ damage. In women identified as high risk, low-dose aspirin started early in pregnancy has been shown to reduce both pre-eclampsia and fetal growth restriction. One study found that aspirin administration considerably reduced growth restriction compared with controls, likely by decreasing tiny clots in the placenta, lowering vascular resistance, and improving the transfer of oxygen and nutrients to the fetus.15Scientific Reports. Early initiation of low-dose aspirin for the prevention of pre-eclampsia in high-risk pregnancies Current guidelines generally recommend that high-risk women start low-dose aspirin before 16 weeks of gestation and continue through delivery. This is a case where the antiplatelet and anti-inflammatory effects of aspirin converge in a setting quite different from heart disease prevention.
Aspirin After Joint Replacement
Hip and knee replacement surgeries carry a well-known risk of blood clots forming in the legs or lungs, and preventing those venous clots has traditionally involved injectable anticoagulants. Aspirin has attracted interest as a simpler, cheaper alternative. A meta-analysis of thirteen randomized trials covering more than 20,000 patients found that aspirin significantly reduced venous clot events compared with placebo and showed similar rates of major bleeding and mortality when compared with other clot-prevention methods.16PubMed Central. Aspirin for venous thromboembolism prophylaxis after hip or knee arthroplasty: An updated meta-analysis of randomized controlled trials That said, when compared head-to-head with anticoagulants, aspirin did not show a statistically significant advantage, so current guidelines vary: some orthopedic societies accept aspirin as a reasonable option for lower-risk patients following joint replacement, while others prefer more potent anticoagulants for higher-risk individuals.
Combining Aspirin With Other Blood Thinners
After certain cardiac procedures like coronary stent placement, doctors frequently prescribe aspirin alongside a second antiplatelet drug such as clopidogrel, prasugrel, or ticagrelor. This combination, known as dual antiplatelet therapy, has become one of the key developments in managing coronary artery disease.17Journal of Thrombosis and Haemostasis. A history of the development of dual antiplatelet therapy for coronary artery disease The second drug blocks a different receptor on the platelet surface, so the two together provide more thorough platelet inhibition than either one alone. The tradeoff is more bleeding, which is why dual therapy is typically time-limited, often six to twelve months after a stent, before stepping down to aspirin alone.
A different and riskier combination is aspirin with a direct oral anticoagulant (DOAC), the newer type of blood thinner often prescribed for atrial fibrillation or venous clots. When patients on a DOAC also took aspirin without a clear indication for the combination, they experienced significantly more bleeding events, particularly non-major bleeds, without any reduction in clot rates.18JAMA Internal Medicine. Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication In other words, the added aspirin produced extra harm with no detectable benefit. This is a surprisingly common clinical scenario: a patient is started on an anticoagulant for one condition, but nobody stops the aspirin they were already taking for another, and the combination just raises bleeding risk.
The Colorectal Cancer Connection
Beyond cardiovascular disease, one of the most intriguing findings about long-term aspirin use is its apparent connection to lower rates of colorectal cancer. This is not simply an incidental observation from a single trial. A large Norwegian registry-based cohort study found that current aspirin use was linked to a roughly 13 percent lower risk of colorectal cancer compared with never use, and the protective association grew stronger with longer duration: people who had been using aspirin for five years or more saw a 16 percent reduction.19PubMed Central. Low-Dose Aspirin and Prevention of Colorectal Cancer: Evidence From a Nationwide Registry-Based Cohort in Norway The researchers estimated that aspirin use prevented more than a thousand cases of colorectal cancer over the study period.
A separate meta-analysis of randomized controlled trial data supported the direction of these findings, concluding that aspirin reduced the overall risk of colorectal cancer recurrence, mortality, and, at low doses, incidence.20PubMed. Does aspirin reduce the incidence, recurrence, and mortality of colorectal cancer? A meta-analysis of randomized clinical trials The mechanism likely involves aspirin’s anti-inflammatory properties, since chronic inflammation in the colon is a known driver of tumor development. Some professional guidelines now suggest that aspirin be considered for colorectal cancer prevention in certain high-risk individuals, though the decision still involves the same bleeding calculus as cardiovascular prevention. The cancer angle does tip the scales for some patients who might not otherwise qualify for aspirin on heart risk alone, which makes it worth discussing with a doctor if you have a family history of colon cancer or other risk factors.